Hong Kong pushes out summer with biotech IPO
Ascletis Pharma is in the market with the first biotechnology IPO in Hong Kong following the bourse’s historic change in listing rules.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: